These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 25351441)
1. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor. Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441 [TBL] [Abstract][Full Text] [Related]
2. Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen. Rajaputra P; Bio M; Nkepang G; Thapa P; Woo S; You Y Bioorg Med Chem; 2016 Apr; 24(7):1540-9. PubMed ID: 26928287 [TBL] [Abstract][Full Text] [Related]
3. Far-red light activatable, multifunctional prodrug for fluorescence optical imaging and combinational treatment. Bio M; Rajaputra P; Nkepang G; You Y J Med Chem; 2014 Apr; 57(8):3401-9. PubMed ID: 24694092 [TBL] [Abstract][Full Text] [Related]
4. Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry. Bio M; Rajaputra P; Nkepang G; Awuah SG; Hossion AM; You Y J Med Chem; 2013 May; 56(10):3936-42. PubMed ID: 23631389 [TBL] [Abstract][Full Text] [Related]
5. Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells. Thapa P; Li M; Karki R; Bio M; Rajaputra P; Nkepang G; Woo S; You Y ACS Omega; 2017 Oct; 2(10):6349-6360. PubMed ID: 29104951 [TBL] [Abstract][Full Text] [Related]
6. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Li M; Nguyen L; Subramaniyan B; Bio M; Peer CJ; Kindrick J; Figg WD; Woo S; You Y J Control Release; 2019 Aug; 308():86-97. PubMed ID: 31299262 [TBL] [Abstract][Full Text] [Related]
7. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy. Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370 [TBL] [Abstract][Full Text] [Related]
8. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy. Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973 [TBL] [Abstract][Full Text] [Related]
9. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release. Xu Z; Hou M; Shi X; Gao YE; Xue P; Liu S; Kang Y Biomater Sci; 2017 Feb; 5(3):444-454. PubMed ID: 28058423 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate. Henne WA; Kularatne SA; Hakenjos J; Carron JD; Henne KL Bioorg Med Chem Lett; 2013 Nov; 23(21):5810-3. PubMed ID: 24064501 [TBL] [Abstract][Full Text] [Related]
11. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles. Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849 [TBL] [Abstract][Full Text] [Related]
12. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007 [TBL] [Abstract][Full Text] [Related]
13. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor. Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300 [TBL] [Abstract][Full Text] [Related]
14. Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy. Thapa P; Li M; Bio M; Rajaputra P; Nkepang G; Sun Y; Woo S; You Y J Med Chem; 2016 Apr; 59(7):3204-14. PubMed ID: 26974508 [TBL] [Abstract][Full Text] [Related]
15. Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA. Zhang Q; Xiang G; Zhang Y; Yang K; Fan W; Lin J; Zeng F; Wu J J Pharm Sci; 2006 Oct; 95(10):2266-75. PubMed ID: 16883559 [TBL] [Abstract][Full Text] [Related]
16. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Gao Y; Li Z; Xie X; Wang C; You J; Mo F; Jin B; Chen J; Shao J; Chen H; Jia L Eur J Pharm Sci; 2015 Apr; 70():55-63. PubMed ID: 25638419 [TBL] [Abstract][Full Text] [Related]
17. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Li M; Thapa P; Rajaputra P; Bio M; Peer CJ; Figg WD; You Y; Woo S J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):521-536. PubMed ID: 28913666 [TBL] [Abstract][Full Text] [Related]
18. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Stevens PJ; Sekido M; Lee RJ Pharm Res; 2004 Dec; 21(12):2153-7. PubMed ID: 15648245 [TBL] [Abstract][Full Text] [Related]
19. Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy. Yang J; Lv Q; Wei W; Yang Z; Dong J; Zhang R; Kan Q; He Z; Xu Y Drug Deliv; 2018 Nov; 25(1):807-814. PubMed ID: 29553858 [TBL] [Abstract][Full Text] [Related]
20. Efficient activation of a visible light-activatable CA4 prodrug through intermolecular photo-unclick chemistry in mitochondria. Bio M; Rajaputra P; Lim I; Thapa P; Tienabeso B; Hurst RE; You Y Chem Commun (Camb); 2017 Feb; 53(11):1884-1887. PubMed ID: 28111669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]